According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of lymphoma non-Hodgkin: diffuse large B- cell lymphoma and follicular lymphoma.
Sannadkii 2010, cilmi-baarayaasha uu hoggaamiyo Irving Weissman, MD, oo ah agaasimaha Stanford Stem Cell Biology and Regenerative Medicine Institute, ayaa muujiyay in ku dhawaad dhammaan unugyada kansarka ay ku daboolan yihiin borotiinka loo yaqaan CD47, kaas oo ciyaari kara "ha i cunin" Signal macrophages.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Bukaannada 22 ee ka qaybqaatay tijaabada, 11 bukaan ayaa si weyn hoos ugu dhigay kansarka kiliinikada, iyo 8 bukaan ayaa meesha ka saaray dhammaan calaamadaha kansarka. Saddexda bukaan ee kale ee tijaabada ku jiray ayaan ka jawaabin daawaynta waxayna u dhinteen horumarka cudurka. Cilmi-baadhayaashu waxay ogaadeen in ka qaybgalayaashu ay leeyihiin kaliya waxyeelooyin yar yar.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
